Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Receivables (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Receivables data on record, last reported at $32000.0 in Q3 2025.

  • For Q3 2025, Receivables fell 77.14% year-over-year to $32000.0; the TTM value through Sep 2025 reached $32000.0, down 77.14%, while the annual FY2024 figure was $75000.0, 44.23% up from the prior year.
  • Receivables reached $32000.0 in Q3 2025 per CRVS's latest filing, down from $86000.0 in the prior quarter.
  • Across five years, Receivables topped out at $1.2 million in Q4 2022 and bottomed at $11000.0 in Q3 2023.
  • Average Receivables over 4 years is $177300.0, with a median of $72500.0 recorded in 2024.
  • Peak YoY movement for Receivables: plummeted 95.58% in 2023, then skyrocketed 1172.73% in 2024.
  • A 4-year view of Receivables shows it stood at $1.2 million in 2022, then tumbled by 95.58% to $52000.0 in 2023, then skyrocketed by 44.23% to $75000.0 in 2024, then plummeted by 57.33% to $32000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $32000.0 in Q3 2025, $86000.0 in Q2 2025, and $79000.0 in Q1 2025.